Repositioning Candidate Details
Candidate ID: | R0748 |
Source ID: | DB05234 |
Source Type: | investigational |
Compound Type: | small molecule |
Compound Name: | LGD2941 |
Synonyms: | -- |
Molecular Formula: | C17H16F6N2O2 |
SMILES: | C[C@@H]1CC[C@H]([C@@H](O)C(F)(F)F)N1C1=CC2=C(NC(=O)C=C2C(F)(F)F)C=C1 |
Structure: |
|
DrugBank Description: | LGD2941 is a non-steroidal, selective androgen receptor modulator (SARM) developed jointly by Ligand and TAP. |
CAS Number: | -- |
Molecular Weight: | 394.3116 |
DrugBank Indication: | For the treatment and prevention of osteoporosis. |
DrugBank Pharmacology: | LGD2941 is a non-steroidal, selective androgen receptor modulator (SARM). SARMs are a novel class of non-steroidal, orally active molecules that selectively modulate the activity of the androgen receptor (AR) in different tissues, providing a wide range of opportunities for the treatment of many diseases and disorders with large patient populations in both men and women. Tissue-selective AR agonists or antagonists may provide utility in male hormone therapy and the treatment of patients with male hypogonadism, female and male osteoporosis, male and female sexual dysfunction, frailty, prostate cancer, hirsutism, acne, androgenetic alopecia and other diseases. |
DrugBank MoA: | LGD2941 selectively modulates the activity of the androgen receptor (AR) in different tissues. |
Targets: | Androgen receptor |
Inclusion Criteria: | Indication associated |

Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
---|
Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
---|
Diseases ID | DO ID | Disease Name | Definition | Class | |
---|---|---|---|---|---|
I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |